Histidyl-isoleucine

Vasoactive intestinal peptide (VIP) has been shown to increase the survival of developing neurons grown in dissociated spinal cord cultures. This result was evident when synaptic activity was blocked with tetrodotoxin (TTX) during a critical period of development (days 7-21 after plating). Other neuropeptides, with a close sequence homology to VIP, have now been tested for their effects on neuronal survival in culture. Within the critical period, the survival of spinal cord neurons was significantly decreased (30-35%) after incubation with 1 nM peptide histidyl-isoleucine amide (PHI-27) or 0.1 nM growth hormone releasing factor (GRF). Neuronal cell death produced by these peptides did not exceed that observed from tetrodotoxin treatment alone. Secretin had no detectable effect on neuronal survival at any of the concentrations tested. In tetrodotoxin-treated cultures, PHI-27 and GRF prevented the neuronal cell death produced by TTX, but only at concentrations greater than 0.1 microM. In contrast, VIP significantly increased neuronal survival at concentrations less than 0.01 nM. The presence of 0.1 nM PHI-27 significantly decreased the effectiveness of VIP in preventing TTX-mediated neuronal cell death. Addition of PHI-27 or VIP, with or without TTX, to one month-old cultures produced no significant change in the number of neurons compared to control cultures. These studies indicate that the survival-promoting effect of VIP is highly structure-dependent and that this action appears to be confined to a critical period of development.